Mechanistic studies of AV370, a potent FGFR3 antagonistic antibody

被引：0

作者：

Bai, Ailin ^{[1
]}

Winston, William ^{[1
]}

Meetze, Kristan ^{[1
]}

Kollipara, Sriram ^{[1
]}

Woo, Jin-Kyeung ^{[1
]}

Nhi Vo ^{[1
]}

Kosmatka, Monica ^{[1
]}

Breault, Lyne ^{[1
]}

Weiler, Solly ^{[1
]}

Kabbarah, Omar ^{[1
]}

Boudrow, Andrea ^{[1
]}

Connolly, Kelly ^{[1
]}

DiPrima, Michael ^{[1
]}

Tissire, Hamid ^{[1
]}

Jiang, Jinwei ^{[1
]}

Gyuris, Jeno ^{[1
]}

Weng, Zhigang ^{[1
]}

机构：

[1] AVEO Pharmaceut Inc, Cambridge, MA USA

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3775

引用

页数：2

共 38 条

[21] Antibody-Based Targeting of FGFR3 in Bladder Carcinoma and t(4;14)-Positive Multiple Myeloma in Mice Editorial Comment
Atala, Anthony
JOURNAL OF UROLOGY, 2010, 183 (02): : 821 - 821
[22] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
Christian Kollmannsberger
Carolyn D. Britten
Anthony J. Olszanski
Joan Andrews Walker
Wei Zang
Melinda D. Willard
David B. Radtke
Daphne L. Farrington
Katherine M. Bell-McGuinn
Amita Patnaik
Investigational New Drugs, 2021, 39 : 1613 - 1623
[23] Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer
Mahmoud Ganji
Shohreh Bakhshi
Alireza Shoari
Reza Ahangari Cohan
Journal of Translational Medicine, 21
[24] Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer
Ganji, Mahmoud
Bakhshi, Shohreh
Shoari, Alireza
Cohan, Reza Ahangari
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[25] Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency
Kuriwaki, Ikumi
Kameda, Minoru
Iikubo, Kazuhiko
Hisamichi, Hiroyuki
Kawamoto, Yuichiro
Kikuchi, Shigetoshi
Moritomo, Hiroyuki
Kondoh, Yutaka
Terasaka, Tadashi
Amano, Yasushi
Tateishi, Yukihiro
Echizen, Yuka
Iwai, Yoshinori
Noda, Atsushi
Tomiyama, Hiroshi
Nakazawa, Taisuke
Hirano, Masaaki
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 33
[26] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer
Kollmannsberger, Christian
Britten, Carolyn D.
Olszanski, Anthony J.
Walker, Joan Andrews
Zang, Wei
Willard, Melinda D.
Radtke, David B.
Farrington, Daphne L.
Bell-McGuinn, Katherine M.
Patnaik, Amita
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1613 - 1623
[27] Expression, purification and biological effect of a novel single chain Fv antibody and protamine fusion protein for the targeted delivery of siRNAs to FGFR3 positive cancer cells
Zang, Chongsen
Liu, Zixuan
Yang, Kunmeng
Li, Rui
Wang, Xinxin
Zhang, Jizhou
Xiao, Yechen
ELECTRONIC JOURNAL OF BIOTECHNOLOGY, 2017, 28 : 14 - 19
[28] Towards high-resolution structure of FGFR3 transmembrane domains through 1H-1H NOESY and TOCSY NMR studies
Soong, Ricky
Herrera, Alvaro
Majumdar, Ananya
Tomich, John
Hristova, Kalina
BIOPHYSICAL JOURNAL, 2007, : 558A - 558A
[29] Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Siefker-Radtke, A. O.
Lugowska, I.
Tupikowski, K.
Andric, Z. G.
Kalebasty, A. Rezazadeh
Curigliano, G.
Vaena, D.
Vogl, F. D.
Currie, G.
Abella, S.
Kelly, W.
ANNALS OF ONCOLOGY, 2019, 30 : 365 - 365
[30] Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
Amrita V. Kamath
Dan Lu
Priyanka Gupta
Denise Jin
Yan Xin
Ann Brady
Jean-Philippe Stephan
Hao Li
Janet Tien
Jing Qing
Lisa A. Damico-Beyer
Cancer Chemotherapy and Pharmacology, 2012, 69 : 1071 - 1078

← 1 2 3 4 →